articleNew England Journal of MedicineJul 23, 2008BRONZE OA

SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study

TSThe SEARCH Collaborative Group

Oxford University Press (United Kingdom) · University of Oxford

PubMed
Indexed incrossrefpubmed

Abstract

Background

Lowering low-density lipoprotein cholesterol with statin therapy results in substantial reductions in cardiovascular events, and larger reductions in cholesterol may produce larger benefits. In rare cases, myopathy occurs in association with statin therapy, especially when the statins are administered at higher doses and with certain other medications.

Methods

We carried out a genomewide association study using approximately 300,000 markers (and additional fine-mapping) in 85 subjects with definite or incipient myopathy and 90 controls, all of whom were taking 80 mg of simvastatin daily as part of a trial involving 12,000 participants. Replication was tested in a trial of 40 mg of simvastatin daily involving 20,000 participants.

Citation impact

2,038
total citations
FWCI
76.20
Percentile
100%
References
27
Citations per year

Authors

1
  • TS
    The SEARCH Collaborative GroupCorresponding

    Oxford University Press (United Kingdom), University of Oxford

Topics & keywords

Keywords
  • Medicine
  • SLCO1B1
  • Statin
  • Myopathy
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Internal medicine
  • Cholesterol
  • Pharmacogenetics
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding